The National Institute of Health has awarded a $3.75 million research grant to a multidisciplinary team of 国产短视频Health researchers to study Long COVID and its potential link to serious neurological impacts that can ultimately lead to dementia and Alzheimer鈥檚 disease 鈥� as well as to explore possible interventions to prevent that.
The grant, awarded in September, funds a five-year investigation with the potential for broad impact, given COVID-19 has burdened an estimated 30 million Americans with neurologic symptoms, according to Subhra Mohapatra, PhD, professor of Molecular Medicine at the 国产短视频Health Morsani College of Medicine and research career scientist at the James A Haley Veterans Hospital, the team鈥檚 lead researcher.
鈥淭hese include dementias and a drop in global cognitive performance,鈥� Dr. Mohapatra said. 鈥淗owever, the exact mechanisms for these disorders are unknown, and how to prevent progression to Alzheimer鈥檚 disease remains an open question.鈥�
Dr. Subhra Mohapatra
That is the mystery to be examined by a diverse team that includes, in addition to Dr. Subhra Mohapatra, Dr. Paula Bickford, a multi-principal investigator and professor of Neurosurgery and Brain Repair; Dr. Shyam Mohapatra, a multi-principal investigator and a professor and director of MCOM鈥檚 Division of Translational Medicine; and co-investigators Drs. Laura Blair, Bala Chandran, and Arunava Roy from the Department of Molecular Medicine; and Dr. Eleni Markoutsa of the Department of Internal Medicine.
Four years ago, as the COVID-19 pandemic swept across the globe, Dr. Subhra Mohapatra and her fellow researchers set out simply to understand how the virus could be prevented and how infected individuals could be treated effectively. But that initial mission soon led to a startling discovery: a link between the condition known as 鈥淟ong COVID鈥� 鈥� when symptoms of COVID persist, rather than resolving after the initial infection, and can include fatigue, dizziness, disturbances in sleep, 鈥渂rain fog,鈥� and eventual neurological problems.
In a series of studies, they found that Long COVID produces a marker for Alzheimer鈥檚 disease called tau 鈥� an accumulation of neurotoxic molecules that create aggregates known as tauopathy. This accumulation leads to memory loss and loss of cognition, the hallmarks of Alzheimer鈥檚. Autopsies of individuals suffering from these symptoms revealed evidence that the virus made its way into the brain through inflammation to cause neurological issues.
It should be noted, Dr. Mohapatra said, that the duration of Long COVID varies 鈥� with many improving significantly over time, while others experiencing symptoms far longer.
The team aims to understand the cellular and molecular mechanisms behind COVID-induced tauopathy and identify potential drug targets to prevent or slow its progression.
鈥淣euro-COVID spanning weeks to months past the time of recovery from COVID-19 illness has afflicted millions of Americans, particularly the aged indviduals 鈥� Dr. Bickford, an expert in the field Aging and brain repair, explained. 鈥淭hough the magnitude of the problem is still being defined, the public health impact is profound due to the number of individuals of all ages who have been or will be infected. There is a great lack of knowledge of the basic neuropathology and how to treat or prevent these conditions.鈥�
In fact, the team鈥檚 approach has been based on finding ways to disrupt the progression. 鈥淐an we find a drug that can halt this progression and prevent people from developing this?鈥� said Dr. Shyam Mohapatra, a nanomedicine expert in the team. 鈥淲e are making progress in that regard. We have preliminary data and are working to test a hypothesis that we can intervene by reducing certain signature proteins we have discovered. These can help in terms of interfering in the process and preventing the disease.鈥�
The danger, Dr. Subhra Mohapatra said, is that Long COVID could lead to a wave of early onset Alzheimer鈥檚 disease in 10 years. The elderly and those with pre-existing medical conditions are at greatest risk for Long COVID and its related neurological issues.
鈥淲e found that with an increase in age, there was a greater accumulation of these neurotoxic tau molecules,鈥� Dr. Mohapatra said. 鈥淎nd we also observed that with age, there is more neuro-inflammation in the brain that includes a classic molecular pathway that is a signature of Alzheimer鈥檚.鈥�
The significance of the team鈥檚 work 鈥� and the magnitude of the research award 鈥� cannot be overstated, said Charles J. Lockwood, MD, MHCM, executive vice president of USF Health and dean of the Morsani College of Medicine.
鈥淭his NIH RO1 award has the potential to significantly impact our understanding of the long-term adverse effects of COVID, provide new insights into the triggers of dementia and eventually help the patients we serve,鈥� he said. 鈥淎t 国产短视频Health, we believe that highly interdisciplinary research can help us tackle complex, real-world challenges, such as this project on Long COVID, which, sadly, will be with us for the foreseeable future. These programs which foster critical thinking, innovation, and collaboration, are vital for addressing the pressing issues of our time."
The team has come a long way since 2020, when it simply set out to learn more about COVID-19 and possible treatments. Dr. Subhra Mohapatra joined 国产短视频Health in 2007 from Moffitt Cancer Center, working first on cancer research, later on viral infections and then on neurodegenerative disease, with a special focus on traumatic brain injuries. When the team began researching COVID, she was instantly drawn to possible effects on the brain.
鈥淭he first question we asked was whether COVID was affecting the brain directly,鈥� she said. 鈥淲e published a paper early on examining how COVID can enter the brain, what are the pathways it can take 鈥� and lo and behold realized that we could see molecular evidence. Our model suggested that it can cause neuroinflammation 鈥� that was very important, because any neurodegenerative disease begins with this inflammation.鈥�
Four years later, they are truly taking their research to an even higher level 鈥� fueled by a landmark grant that underscores the vital importance of their work.